microRNA-32在多发性骨髓瘤中的表达及临床意义

Expression and significance of microRNA-32 in multiple myeloma

目的探讨microRNA-32(miR-32)在多发性骨髓瘤(MM)骨髓单个核细胞(BMMNC)中的表达水平及意义。方法收集43例MM患者及20例正常对照的骨髓标本,采用实时荧光定量PCR法检测BMMNC中miR-32的表达,并分析其与Durie-Salmon(D-S)分期和β2-微球蛋白(β2-MG)水平的关系。结果 miR-32在MM中的表达水平(5.29±0.31)明显高于正常对照组(相对值为1),复发/难治组miR-32表达水平(6.86±0.24)明显高于初治组(4.15±0.29),差异均有统计学意义(P<0.05)。MM患者化疗后miR-32表达水平较化疗前明显降低(5.29±0.31 vs.3.43±0.45),化疗有效组降低十分显著(4.57±0.41 vs.1.92±0.15),差异均有统计学意义(P<0.05);无效/进展组miR-32表达水平化疗前后无明显改变。miR-32表达与MM D-S分期和β2-MG水平有关。结论 miR-32表达在MM的发生、发展中发挥着重要作用,有望成为MM疾病进展和疗效的预测指标。

Objective To explore the expression of microRNA-32（miR-32） in multiple myeloma（ MM）, and the relationship of its expression with clinical features. Methods The expression levels of miR-32 in bone marrow mono-nuclear cells of MM patients and 20 normal controls were examined by real-time polymerase chain reaction. The association of miR-32 in MM with 132-microglobulin （β2-MG） and Durie-Salmon（D-S） staging was further studied. Results The expression of miR-32 in MM patients（ 5.29±0. 31 ） was obviously higher than that in normal control（ the relative value was set as 1 ） with statistical differences（ P〈O. 05 ）. The expression of miR-32 in relapsed/refractory MM patients was obviously higher than that in newly diagnosed patients （6. 86±0. 24 vs, 4. 15±0. 29） with statistical significance（P〈O. 05）. The expression of miR-32 in MM patients after chemotherapy was lower than that before treat- ment（ 5.29±0. 31 vs. 3.43±0. 45 ） , especially in effective group （ 4. 57±0. 41 vs. 1.92±0. 15 ）, showing significant differences （ P〈 O. 05 ）. There was no statistical differences in ineffective/progress group before and after chemotherapy （P〉O. 05 ）.The expression of miR-32 was associated with D-S staging and 132-MG of MM. Conclusion Expression of miR-32 in MM plays an important role in the development and progression of MM, and is possible to become a predictor of disease progression and efficacy in MM.